Department of Biological and Chemical Sciences, New York Institute of Technology, Old Westbury, New York, USA.
Nucleic Acid Ther. 2021 Oct;31(5):321-323. doi: 10.1089/nat.2021.0013. Epub 2021 May 6.
The utilization of the RNA-based Pfizer-BioNTech and Moderna coronavirus disease 2019 (COVID-19) vaccines represents the culmination of many years of nonviral nucleic acid delivery, but more importantly, they signify a massive clinical . Scientists working in the area of nucleic acid delivery using lipid nanoparticles will undoubtedly be energized by the success of these vaccines and begin to collect much needed data in the realm of nonviral-based RNA delivery, specifically, the use of lipid nanoparticles, the immune response, safety, and efficacy. It is easily conceivable that in the future we can utilize these data to streamline our approach for the delivery of for gene therapy and therapeutic and regenerative medicine (ie, wound repair) applications
基于 RNA 的辉瑞-生物技术和 Moderna 新型冠状病毒病 2019（COVID-19）疫苗的利用代表了多年非病毒核酸传递的成果，但更重要的是，它们标志着大规模的临床应用。使用脂质纳米颗粒进行核酸传递的科学家们无疑将受到这些疫苗成功的鼓舞，并开始在非病毒 RNA 传递领域收集急需的数据，特别是脂质纳米颗粒的使用、免疫反应、安全性和疗效。可以想象，在未来，我们可以利用这些数据来简化我们的基因治疗和治疗性和再生医学（例如伤口修复）应用的传递方法。
